IGC Pharma (IGC) Financial Statements & Analysis

IGC Pharma (IGC) Income Statement

IGC Pharma reported revenue of $1.19M in fiscal 2026 (fiscal year ended Mar 31, 2026), down 6.7% from $1.27M a year earlier. IGC Pharma posted a net loss of $6.55M, compared with a net loss of $7.12M a year earlier. Gross margin was 29.7% and operating margin -860.3%. In the most recent quarter, Q1 fiscal 2027 (ended Jun 30, 2026), revenue was $265.00K, down 16.4% from the same quarter a year earlier.

IGC Pharma Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

IGC Pharma, Inc. income statement - Annual data in millions USD
Breakdown	FY 2026	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Mar 2026	Mar 2025	Mar 2024	Jun 2023	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017
Revenue & Gross Profit
Revenue	1.19	1.27	1.35	0.91	0.91	0.40	0.90	4.07	5.12	2.19	0.58
Cost of Revenue	0.83	0.65	0.61	1.07	0.47	0.20	0.79	3.96	4.98	2.11	0.36
Gross Profit	0.35	0.62	0.73	-0.16	0.44	0.19	0.11	0.12	0.13	0.08	0.22
Operating Expenses
Research & Development	5.19	3.66	3.77	3.46	3.46	2.33	0.93	1.01	1.26	0.14	0.11
Selling, General & Administrative	5.36	4.41	6.76	7.95	8.55	13.29	7.91	5.97	3.52	1.87	2.27
Operating Expenses	10.56	8.07	10.53	11.41	12.01	15.62	8.84	6.98	4.78	1.87	2.27
Operating Income	-10.20	-7.45	-9.80	-11.57	-11.57	-15.43	-8.72	-6.86	-4.64	-1.79	-2.05
Other Income/Expense
Interest Income	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00	0.00	0.12
Interest Expense	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00	0.03	0.22
Other Income/Expense	3.66	0.33	-3.20	0.07	0.07	0.41	-0.09	-0.45	0.55	0.00	0.22
Income
Income Before Tax	-6.55	-7.12	-13.00	-11.51	-11.51	-15.02	-8.81	-7.32	-4.10	-1.79	-1.84
Income Tax Expense	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00	0.00	0.01
Net Income	-6.55	-7.12	-13.00	-11.51	-11.51	-15.02	-8.81	-7.32	-4.10	-1.79	-1.87
Net Income - Continuous Operations	-6.55	-7.12	-13.00	-11.51	-11.51	-15.02	-8.81	-7.32	-4.10	-1.79	-1.87
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-6.22	-6.98	-9.16	-10.85	-10.91	-14.37	-8.25	-6.72	-4.58	-1.74	-1.22
EBIT	-	-7.45	-9.80	-	-11.57	-15.43	-8.72	-	-	-	-
Depreciation & Amortization	0.32	0.46	0.64	0.66	0.66	0.65	0.48	0.14	0.06	0.02	0.40
Earnings Per Share
Basic EPS	-	-	-	-	-	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-
Basic Shares Outstanding	95.04	76.52	58.84	52.58	52.58	49.99	41.96	39.49	35.39	27.94	25.66
Diluted Shares Outstanding	95.04	76.52	58.84	52.58	52.58	49.99	41.96	39.49	35.39	27.94	25.66

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About IGC Pharma Financial Statements

What was IGC Pharma's revenue in fiscal 2026?

IGC Pharma reported revenue of $1.19M in fiscal 2026 (fiscal year ended Mar 31, 2026). That was down 6.7% from $1.27M a year earlier.

Is IGC Pharma profitable?

No. IGC Pharma reported a net loss of $6.55M in fiscal 2026. In fiscal 2025 it lost $7.12M.

What is IGC Pharma's operating margin?

IGC Pharma's operating income was −$10.20M on revenue of $1.19M in fiscal 2026, an operating margin of -860.3%, compared with -585.8% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition